Another significant biomarker in a subset of early BC is represented by BRCA1/2 mutational status, whose testing holds importance for risk stratification, patients’ selection for treatment with PARP inhibitors, and genetic screening in high-risk individuals [8]. The gene discussed is BRCA1; the disease is breast cancer.